Linaclotide (Linzess) for Functional Constipation

Found an issue? Give us feedback

The Medical Letter o...arrow_drop_down

The Medical Letter on Drugs and Therapeutics

Article . 2023 . Peer-reviewed

Data sources: Crossref

The Medical Letter on Drugs and Therapeutics

Article . 2023

Data sources: Europe PubMed Central

Linaclotide (Linzess) for Functional Constipation

descriptionPublicationkeyboard_double_arrow_right Article 21 Aug 2023Publisher:The Medical Letter, Inc.Journal:The Medical Letter on Drugs and Therapeutics, volume 65, pages 135-136 (eissn: 1523-2859,

Copyright policy )

doi: 10.58347/tml.2023.1683d

pmid: 37651297

Linaclotide (Linzess) for Functional Constipation

- Summary
- Subjects
- Metrics

Abstract

The guanylate cyclase-C receptor agonist linaclotide (Linzess – Abbvie/Ironwood) was first approved by the FDA in 2012 for treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation in adults.

Keywords

Humans, Peptides, Constipation

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average